Annual CFF
$1.85 M
-$64.52 M-97.21%
December 31, 2022
Summary
- As of February 10, 2025, NBRV annual cash flow from financing activities is $1.85 million, with the most recent change of -$64.52 million (-97.21%) on December 31, 2022.
- During the last 3 years, NBRV annual CFF has fallen by -$54.22 million (-96.70%).
Performance
NBRV Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
-$4.85 M
-$4.19 M-636.27%
March 31, 2023
Summary
- As of February 10, 2025, NBRV quarterly cash flow from financing activities is -$4.85 million, with the most recent change of -$4.19 million (-636.27%) on March 31, 2023.
- Over the past year, NBRV quarterly CFF has dropped by -$7.05 million (-321.15%).
Performance
NBRV Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
-$5.20 M
-$7.05 M-380.66%
March 31, 2023
Summary
- As of February 10, 2025, NBRV TTM cash flow from financing activities is -$5.20 million, with the most recent change of -$7.05 million (-380.66%) on March 31, 2023.
- Over the past year, NBRV TTM CFF has dropped by -$38.83 million (-115.45%).
Performance
NBRV TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NBRV Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -97.2% | -321.1% | -115.5% |
| 3 y3 years | -96.7% | +83.9% | -132.1% |
| 5 y5 years | -97.4% | -125.5% | -109.3% |
NBRV Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -97.2% | at low | -321.1% | at low | -107.8% | at low |
| 5 y | 5-year | -97.2% | at low | -112.3% | +522.8% | -105.6% | at low |
| alltime | all time | -98.6% | -24.1% | -105.3% | +522.8% | -103.7% | +30.0% |
Nabriva Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$4.85 M(+636.3%) | -$5.20 M(-380.7%) |
| Dec 2022 | $1.85 M(-97.2%) | -$659.00 K(-159.5%) | $1.85 M(-60.2%) |
| Sep 2022 | - | $1.11 M(-239.9%) | $4.65 M(-38.9%) |
| Jun 2022 | - | -$792.00 K(-136.1%) | $7.61 M(-77.4%) |
| Mar 2022 | - | $2.19 M(+2.6%) | $33.63 M(-49.3%) |
| Dec 2021 | $66.37 M(+146.5%) | $2.14 M(-47.5%) | $66.37 M(-15.2%) |
| Sep 2021 | - | $4.07 M(-83.9%) | $78.25 M(+0.4%) |
| Jun 2021 | - | $25.23 M(-27.8%) | $77.91 M(-15.4%) |
| Mar 2021 | - | $34.93 M(+149.1%) | $92.07 M(+242.0%) |
| Dec 2020 | $26.92 M(-52.0%) | $14.02 M(+275.4%) | $26.92 M(-25.8%) |
| Sep 2020 | - | $3.73 M(-90.5%) | $36.30 M(-29.9%) |
| Jun 2020 | - | $39.39 M(-230.3%) | $51.81 M(+220.3%) |
| Mar 2020 | - | -$30.22 M(-229.2%) | $16.18 M(-71.2%) |
| Dec 2019 | $56.08 M(-39.7%) | $23.39 M(+21.5%) | $56.08 M(-1.6%) |
| Sep 2019 | - | $19.25 M(+413.5%) | $57.01 M(-32.2%) |
| Jun 2019 | - | $3.75 M(-61.3%) | $84.13 M(+0.7%) |
| Mar 2019 | - | $9.68 M(-60.2%) | $83.54 M(-10.1%) |
| Dec 2018 | $92.92 M | $24.33 M(-47.5%) | $92.92 M(+38.9%) |
| Sep 2018 | - | $46.38 M(+1368.1%) | $66.89 M(-30.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $3.16 M(-83.4%) | $95.68 M(+3.5%) |
| Mar 2018 | - | $19.06 M(-1214.6%) | $92.45 M(+28.0%) |
| Dec 2017 | $72.22 M(+223.8%) | -$1.71 M(-102.3%) | $72.22 M(-24.8%) |
| Sep 2017 | - | $75.17 M(<-9900.0%) | $95.99 M(+361.0%) |
| Jun 2017 | - | -$73.00 K(-93.8%) | $20.82 M(-1.3%) |
| Mar 2017 | - | -$1.17 M(-105.3%) | $21.10 M(-5.4%) |
| Dec 2016 | $22.30 M(-83.2%) | $22.06 M(>+9900.0%) | $22.30 M(-430.3%) |
| Sep 2016 | - | $6000.00(-97.1%) | -$6.75 M(-108.0%) |
| Jun 2016 | - | $208.00 K(+617.2%) | $84.91 M(-34.2%) |
| Mar 2016 | - | $29.00 K(-100.4%) | $129.04 M(-3.0%) |
| Dec 2015 | $133.02 M(+1362.1%) | -$7.00 M(-107.6%) | $133.02 M(-5.0%) |
| Sep 2015 | - | $91.66 M(+106.7%) | $139.95 M(+154.4%) |
| Jun 2015 | - | $44.34 M(+1006.9%) | $55.01 M(+401.4%) |
| Mar 2015 | - | $4.01 M(-6052.5%) | $10.97 M(+20.6%) |
| Dec 2014 | $9.10 M(+547.2%) | -$67.30 K(-101.0%) | $9.10 M(-0.7%) |
| Sep 2014 | - | $6.73 M(+2117.5%) | $9.17 M(+276.4%) |
| Jun 2014 | - | $303.50 K(-85.8%) | $2.44 M(+14.2%) |
| Mar 2014 | - | $2.13 M | $2.13 M |
| Dec 2013 | $1.41 M | - | - |
FAQ
- What is Nabriva Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Nabriva Therapeutics?
- What is Nabriva Therapeutics annual CFF year-on-year change?
- What is Nabriva Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Nabriva Therapeutics?
- What is Nabriva Therapeutics quarterly CFF year-on-year change?
- What is Nabriva Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Nabriva Therapeutics?
- What is Nabriva Therapeutics TTM CFF year-on-year change?
What is Nabriva Therapeutics annual cash flow from financing activities?
The current annual CFF of NBRV is $1.85 M
What is the all time high annual CFF for Nabriva Therapeutics?
Nabriva Therapeutics all-time high annual cash flow from financing activities is $133.02 M
What is Nabriva Therapeutics annual CFF year-on-year change?
Over the past year, NBRV annual cash flow from financing activities has changed by -$64.52 M (-97.21%)
What is Nabriva Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NBRV is -$4.85 M
What is the all time high quarterly CFF for Nabriva Therapeutics?
Nabriva Therapeutics all-time high quarterly cash flow from financing activities is $91.66 M
What is Nabriva Therapeutics quarterly CFF year-on-year change?
Over the past year, NBRV quarterly cash flow from financing activities has changed by -$7.05 M (-321.15%)
What is Nabriva Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NBRV is -$5.20 M
What is the all time high TTM CFF for Nabriva Therapeutics?
Nabriva Therapeutics all-time high TTM cash flow from financing activities is $139.95 M
What is Nabriva Therapeutics TTM CFF year-on-year change?
Over the past year, NBRV TTM cash flow from financing activities has changed by -$38.83 M (-115.45%)